GelteqGELS -3.65%8 Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus rates GELS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 950 Drug Manufacturers companies, Gelteq ranks better than 64.53% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Gelteq's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Gelteq's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.03 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Gelteq Receivables Turnover Related Terms
Gelteq Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Gelteq's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GELS vs YCBD, AKAN, SNOA: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gelteq's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gelteq Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gelteq's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Gelteq's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gelteq (GELS) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gelteq and its competitors. According to the industry distribution chart, Gelteq ranks #337 out of 950 companies in the Drug Manufacturers industry, placing it in the top 35.5%.
Is Gelteq's Receivables Turnover too high?
Gelteq's current Receivables Turnover is 0.00. Based on the distribution chart, Gelteq ranks #337 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gelteq has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's Receivables Turnover compare to YCBD and AKAN?
According to the Drug Manufacturers industry distribution chart, Gelteq ranks #337 out of 950 companies for Receivables Turnover. This puts Gelteq in the upper half of its industry. The industry median Receivables Turnover is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gelteq and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gelteq's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Gelteq's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Gelteq (GELS), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
8GF Score
Get the complete analysis for GELS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GELS has been successfully added to your 
